COVID-19 and Cardiovascular Disease: Direct Consequences and Lines of Investigation
DOI:
https://doi.org/10.24950/R/110/20/3/2020Keywords:
COVID-19, Cardiovascular Diseases, Coronavirus InfectionsAbstract
SARS-COV-2 infection has left no one unscathed or indifferent. It has had profound implications for personal daily lives and health, but also at a broader economic and social level. In terms of cardiovascular disease, COVID-19 had a huge impact. Much remains unknown and the information is often contradictory. This article aims to point out lines of investigation that may be useful to find answers about the link between SARS-COV-2 infection and cardiovascular disease. We explore the known direct effects of the disease, addressing the pathophysiological mechanisms, whether it is the direct cell aggression, inflammatory storm, thrombotic angiopathy, hypoxia or lipoprotein dysfunction.
Downloads
References
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 (in press). doi:10.1001/jamacardio.2020.0950
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, for the China Medical Treatment Expert Group for Covid-19. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020 (in press). doi: 10.1183/13993003.00547-2020
Wang Z, Chen Z, Zhang L, for the China Hypertension Survey Investigators. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015. Circulation. 2018;137:2344-56. doi: 10.1161/CIRCULATIONAHA.117.032380.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA.
;323:1574-81. doi:10.1001/jama.2020.5394
Barison A, Aimo A, Castiglione V, Arzilli C, Lupón J, Codina P, et al. Cardiovascular disease and COVID-19: les liaisons dangereuses. Eur J Prev Cardiol. 2020 (in press). doi: 10.1177/2047487320924501.
Dixon DL, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz AH, Kakavand H,et al. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). J Cardiovasc Pharmacol. 2020;75:359-67. doi: 10.1097/FJC.0000000000000836.
Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020 (in press).
doi:10.1093/eurheartj/ehaa286.
Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 (in press).doi:10.1001/jamacardio.2020.1096
Boukhris M, Hillani A, Moroni F, Annabi MS, Addad F, Ribeiro MH, et al. Cardiovascular implications of the COVID-19 pandemic: a global perspective. Can J Cardiol. 2020 (in press). doi: 10.1016/j.cjca.2020.05.018
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061-9. doi:10.1001/jama.2020.1585
Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020 (in press). doi: 0.1097/CM9.0000000000000744.
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 (in press). doi: 10.1001/jamacardio.2020.1017.
Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378:345-53. doi: 10.1056/NEJMoa1702090
Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M et al. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes. Circulation. 2020 (in press). doi:10.1161/CIRCULATIONAHA.120.047525
Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.Cardiovasc Res. 2020 (in press). doi:10.1093/cvr/cvaa106
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.
Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19.]. Thromb Res. 2020 (in press). doi:10.1016/j.thromres.2020.04.013
Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry. 2020 (in press). doi:10.1136/jnnp-2020-323586
Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med. 2020;382:e60. doi:10.1056/NEJMc2009787
Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res. 2020;30:367-369. doi:10.1038/s41422-020-0327-4
Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631-7. doi:10.1002/path.1570
Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY,et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020 (in press). doi:10.1016/j.kint.2020.04.003
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-8. doi:10.1016/S0140-6736(20)30937-5
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 (in press). doi:10.1056/NEJMoa2015432
Buja LM, Wolf DA, Zhao B, Akkanti B, McDonald M, Lelenwa L, et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol. 2020;48:107233. doi:10.1016/j.carpath.2020.107233
Zhu H, Rhee JW, Cheng P, Waliany S, Chang A, Witteles RM, et al. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response [published correction appears in Curr Cardiol Rep. 2020;22:36]. Curr Cardiol Rep. 2020;22:32. doi:10.1007/s11886-020-01292-3
Tufan A, Avanoglu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50:620-32. doi:10.3906/sag-2004-168
Wang W, He J, Lie p, Huang l, Wu S.. The definition and risks of cytokine release syndrome-like in 11 COVID19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis. Med Rxiv 2020. doi: 10.1101/2020.02.26.20026989
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020]. Lancet. 2020;395:497-506. doi:10.1016/S0140-6736(20)30183-5
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published correction appears in Intensive Care Med. 2020]. Intensive Care Med. 2020;46:846-8. doi:10.1007/s00134-020-05991-x
Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease [published online ahead of print, 2020]. Eur J Heart Fail. 2020 (in press). doi:10.1002/ejhf.1871
Rello J, Storti E, Belliato M, Serrano R. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020;55:2001028. doi:10.1183/13993003.01028-2020
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20. doi:10.1056/NEJMoa2002032
Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259-60. doi:10.1038/s41569-020-0360-5
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72:2231-64. doi:10.1016/j.jacc.2018.08.1038
Gattinoni L, Coppola S, Cressoni M. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 (in press).
Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19.]. Ann Intern Med. 2020 (in press). doi:10.7326/M20-2003
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094-99. doi:10.1111/jth.14817
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-7. doi:10.1111/jth.14768
Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiol Cardiothorac Imaging 2020;2:e200067-e200067
Kreuziger L, Lee A, Garcia D, Cuker A, Cushman M, Connors J. COVID-19 and VTE-anticoagulation. American Society of Hematology - resource for COVID-19 and coagulopathy 2020. Chicago: ASH; 2020.
Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation. J Thromb Thrombolysis. 2020 (in press). doi:10.1007/s11239-020-02138-z
Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19.Eur Heart J Cardiovasc Pharmacother. 2020 (in press). doi:10.1093/ehjcvp/pvaa036
Gordon EM, Figueroa DM, Barochia AV, Yao X, Levine SJ. High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease. Front Pharmacol. 2016;7:323.
Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation. 2001;103:2283-88. doi:10.1161/01.
cir.103.18.2283
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
